ClinicalTrials.gg
RecruitingNCT05489289Updated Mar 12, 2025

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

A Phase 3 interventional study of AK104 and placebo in Hepatocellular Carcinoma, sponsored by Akeso. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
570
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cadonilimab in Carcinoma, Hepatocellular — 13 open to participants now, 16 under way, 2 of them phase 3. cadonilimab · Carcinoma, Hepatocellular.

Planned enrollment
Largest of 23
570 · median 36
Started
2023
with 6 others
Phase 3
2 of 23
2 open now
Primary completion
2026-01
later than 8 of 15 live
Registered
4th of 23
by date
Lead sponsor
6 of 23
Akeso

Among the 23 studies testing cadonilimab in Carcinoma, Hepatocellular, this one has the largest planned enrollment, is one of 7 that started in 2023, is one of 2 in phase 3, reaches primary completion later than 8 of the 15 other live ones, and was the 4th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

13 of the 23 studies testing cadonilimab in Carcinoma, Hepatocellular are open now, in 2 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About cadonilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cadonilimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pathological diagnosis of HCC without any ;
  2. Receiving radical resection as the only anti-tumor treatment;
  3. No evidence of residual cancer found during or after the operation;
  4. Presence of any high risk factor of postoperative recurrence;
  5. grade: A;
  6. score: 0;
  7. Controlled underlying causes of HCC.

Exclusion criteria

Exclusion Criteria:

  1. Fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc;
  2. Any anti-tumor treatment other than radical surgery before randomization;
  3. Precarious liver function indicated by severe complications;
  4. Recent procedures or medications leading to high risk of bleeding;
  5. Poorly controlled or symptomatic hypertension, congestive heart failure, arrhythmia, etc;
  6. Failure of performing enhanced CT or MRI scans of the liver;
  7. Recent severe infections or systemic antibiotics use;
  8. Active diseases;
  9. History of other incurable malignant tumors;
  10. History of transplantation;
  11. Pregnancy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
570 participants (estimated)

Study arms

  • Active comparator
    AK104

    AK104 IV every three weeks

    Biological: AK104

  • Placebo comparator
    placebo

    Placebo IV every three weeks

    Biological: placebo

Interventions

  • BiologicalAK104

    Subjects will receive AK104 until disease progression or for a maximum of 16 cycles

  • Biologicalplacebo

    Subjects will receive placebo until disease progression or for a maximum of 16 cycles

06

What researchers measure

Primary outcomes

  1. Recurrence free survival (RFS) by BICR

    The time comfirmed by BICR from randomization to recurrence or death.

    Time frame: Up to 48 months

Secondary outcomes

  1. 12-months recurrence free survival (RFS-12)

    The proportion of patients without recurrence or death at 12 month.

    Time frame: 12 months

  2. 24-months recurrence free survival (RFS-24)

    The proportion of patients without recurrence or death at 24 month.

    Time frame: 24 months

  3. Time to recurrence (TTR)

    The time from randomization to recurrence.

    Time frame: Up to 48 months

  4. Overall survival (OS)

    The time from randomization to death for any reason.

    Time frame: Up to 48 months

  5. Types and proportions of adverse events (AEs)

    Time frame: Up to 48 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2026, 36 months after the start.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's planned 36 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2022
First posted
Aug 5, 2022
StartActual
Jan 5, 2023
Primary completionEst.
Jan 28, 2026
CompletionEst.
Jan 1, 2027
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05489289
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Aug 5, 2022
Start date
Jan 5, 2023
Primary completion
Jan 28, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Mar 12, 2025

Study contacts

Ting Liu, M.D.
Contact
clinicaltrials@akesobio.com
(0760)89873999
Jia Fan, Ph.D.
principal investigator · Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion